Welcome to our dedicated page for Therapeutic Solutions Intl news (Ticker: TSOI), a resource for investors and traders seeking the latest updates and insights on Therapeutic Solutions Intl stock.
Therapeutic Solutions International, Inc. (TSOI) generates a steady flow of news centered on immune modulation, stem cell therapy, immunotherapy, and nutraceutical development. This news page aggregates company announcements so readers can follow how its clinical-stage programs, patents, and subsidiaries evolve over time.
Recent press releases highlight progress with the company’s JadiCell universal donor stem cell product in areas such as lung inflammation, COVID-19–related conditions, ARDS, epilepsy, and ALS. News items also cover mechanistic discoveries about how JadiCells interact with immune cells, as well as data suggesting that these cells may enhance gene therapy–mediated production of therapeutic cells.
Another major stream of updates involves the nutraceutical QuadraMune. The company has announced multiple patents related to QuadraMune’s effects on immune pathways, including natural killer cell activity, viral inhibition, brain protection, and modulation of regulatory T cells. These developments are reflected in patent-related news and scientific commentary from company representatives.
Therapeutic Solutions International also issues news about its subsidiaries and pre–spin-off entities, such as Campbell Neurosciences in suicide prevention, Res Nova Bio in oncology immunotherapy, Epilepsy Bio in epilepsy, and ALS Biologics in ALS. Announcements may describe clinical observations under Right To Try, plans for public listings, loyalty dividends of subsidiary shares, and strategic positioning of intellectual property.
In addition, the company has released statements on legal actions and corporate decisions, including its plan to voluntarily delist and "go dark" from the public markets. Investors and observers can use this news feed to review historical announcements on clinical progress, patents, subsidiary formation, legal matters, and capital markets strategy related to TSOI.
Therapeutic Solutions International (TSOI) has announced its intention to voluntarily delist from public markets and 'go dark.' The decision, approved by the Board of Directors and majority shareholders on April 22, 2025, comes after the company's market cap dropped from $400 million to below $10 million over three years, with shares trading at $0.0001.
The company will initiate the delisting process through Form 8-K filing, followed by Form 25 and Form 15 submissions after mandatory 10-day waiting periods. CEO Timothy G Dixon describes this move as a strategic pause rather than surrender, aimed at escaping what he terms 'toxic cycle of dilution and manipulation.'
During this period, TSOI will focus on its subsidiaries: Breathe Biologics, Campbell Neurosciences, and Res Nova Bio. The company plans to explore potential sales or partnerships of these subsidiaries, with a commitment to return a portion of any proceeds to shareholders through dividends or stock buybacks.
Therapeutic Solutions International (TSOI) has received a Notice of Allowance from the US Patent and Trademark Office for a patent on using T regulatory cells to enhance the efficacy of mesenchymal stem cells in treating lung inflammation. This patent covers a method to reduce lung inflammation through the administration of T regulatory cells combined with mesenchymal stem cells. The company is developing treatments for COVID-19, ARDS, COPD, and pulmonary fibrosis, all involving lung inflammation. The patent is expected to increase TSOI's value, with comparisons to successful deals in the sector, such as Regeneron-Sonoma and Quell-AstraZeneca.
Therapeutic Solutions International's pre-spin-off company, Campbell Neurosciences, appoints Raymond Oliver as Chairman of the Board to facilitate its entry into the capital markets. The company plans to distribute up to 10,000,000 shares to existing shareholders in a loyalty dividend. Campbell Neurosciences is focused on developing innovative technologies for the treatment of psychiatric diseases and suicidal propensities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Therapeutic Solutions Intl (TSOI)?
What is the market cap of Therapeutic Solutions Intl (TSOI)?
